Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM) (dalbavancin hydrochloride)

Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for
Dalvance(TM) (dalbavancin hydrochloride)

PDUFA Action Date of May 26, 2014

CHICAGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced that the New Drug Application (NDA) for its
investigational drug, Dalvance™ (dalbavancin hydrochloride) for injection, has
been accepted for priority review by the U.S. Food and Drug Administration
(FDA) with an action date of May 26, 2014. Durata is seeking FDA approval of
Dalvance™ for the treatment of patients with acute bacterial skin and skin
structure infections (ABSSSI) caused by susceptible Gram-positive
microorganisms, including MRSA (methicillin resistant Staphylococcus aureus).

The NDA, submitted on September 26, 2013, was based on the entire data set
from Durata Therapeutics' clinical development program, including results from
two Phase 3 trials DISCOVER 1 and DISCOVER 2, as well as a previous Phase 3
study (VER001-9). Both DISCOVER 1 and DISCOVER 2 trials were conducted under a
Special Protocol Assessment (SPA) with the FDA.

"We are very pleased with the FDA's acceptance for filing of our NDA, as this
represents an important achievement in the development of Dalvance™.We
believe that Dalvance™ has the potential to make a meaningful difference in
the lives of patients with ABSSSI," said Paul R. Edick, Durata Therapeutics
Chief Executive Officer. "If approved by the FDA, Dalvance™, with its once
weekly dosing, may help facilitate an important shift in treatment from the
hospital to ambulatory settings."


For the six month period of January to June 2010, a projected 9.2 million
patients were treated in U.S. hospitals for infections of any type, and nearly
17 percent of the diagnostic category presentations were for skin and skin
structure infections (SSSIs). Of these presentations for SSSI, approximately
74 percent were disease types included in ABSSSI.^i This category of infection
increased by 176 percent from 1997 to 2009 in hospitalized patients.^ii The
majority of skin and soft tissue infections in hospitalized patients are
caused by Staphylococcus aureus, and approximately 59 percent of these
infections are estimated to be caused by MRSA in the U.S.^iii,iv Failure to
successfully treat ABSSSI may result in hospital readmissions. Under the new
health care reform laws, hospitals may incur financial penalties for
preventable hospital readmissions, including unresolved infections.


Dalvance™ (dalbavancin hydrochloride) for injection is a second generation,
semi-synthetic lipoglycopeptide, which consists of lipophilic side-chains
attached to glycopeptides. When compared to vancomycin, Dalvance™ has a longer
half-life resulting in a duration of antibacterial activity of 5-7 days per
dose.^vIf approved, Dalvance™ would be the first drug for ABSSSI requiring
once-weekly 30-minute intravenous doses (1000 mg on Day 1 and 500 mg on Day
8). This may shorten the length of stay for patients who are hospitalized and,
for appropriate patients, enable therapy in an outpatient setting eliminating
the hospital admission altogether.^vi Ultimately, this may lower the overall
cost of care for these patients.


Durata Therapeutics, Inc. is a pharmaceutical company focused on the
development and commercialization of novel therapeutics for patients with
infectious diseases and acute illnesses. Durata has completed two global Phase
3 clinical trials with its lead product candidate, Dalvance™, for the
treatment of patients with acute bacterial skin and skin structure infections,


Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include statements about the
FDA approval of Dalvance™ and the potential impact of Dalvance's™ dosing
schedule on hospital costs and readmissions. Actual results may differ
materially from those indicated by these forward-looking statements as a
result of various important factors, including those discussed in the "Risk
Factors" section of our most recent quarterly report on Form 10-Q, which is on
file with the SEC and is also available on our website. In addition, any
forward-looking statements represent our views only as of today and should not
be relied upon as representing our views as of any subsequent date. While we
may elect to update these forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so, even if our views
change. Therefore, you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.

^i AMR Hospital Antibiotic Market Guide - Book 2: Diagnosis and Surgery
Reports, January 2010 – June 2010.

^ii Giuliano C, Kale-Pradhan P, et al. Early Response of Ceftaroline Fosamil
in the Treatment of Soft-tissue Infections. Expert Rev Clin Pharmacol.
5(5):509-512 (2012).

^iii Moet G, Jones R, et al. Contemporary causes of skin and soft tissue
infections in North America, Latin America and Europe: Report from the SENTRY
Antimicrobial Surveillance Program (1998-2004). Diagnostic Microbiology and
Infectious Disease. 57, 7-13 (2007).

^iv Moran GJ, Krishnadasan A, Gorwitz RJ et al.; EMERGEncy ID Net Study Group.
Methicillin-resistant S. aureus infections among patients in the emergency
department. N. Engl. J. Med. 355(7), 666–674 (2006).

^v Durata DOF.

^vi Durata Therapeutics website. About dalbavancin.
(Durata DOF)

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         Media Relations Contact
         Geoff Curtis
         DJE Science
         (312) 233-1253

Durata Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.